GILD
GILD
GILD
Gilead Sciences Inc has announced that it expands Lenacapavir access with a new PAHO deal in Latin America. Against this strategic move, the company holds a market capitalization of $187,470,843,125 and generated full-year revenue of $29,442,000,000. Its current financial metrics also show a TTM EPS of -2.61, a PE ratio of -58.075, and a solid free cash flow yield of 7.04%.
Based on zacks.comGilead Sciences (GILD) Rises Higher Than Market: Key Facts
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
The Big 3: MRK, GILD, XOM
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.